SK Biopharmaceuticals Co Ltd
KRX:326030
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
75 700
125 900
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
SK Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co Ltd
Net Income (Common)
SK Biopharmaceuticals Co Ltd
Net Income (Common) Peer Comparison
000100
008930
128940
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Net Income (Common)
-₩32.9B
|
CAGR 3-Years
49%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Net Income (Common)
₩147.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
29%
|
CAGR 10-Years
6%
|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Net Income (Common)
₩118B
|
CAGR 3-Years
57%
|
CAGR 5-Years
44%
|
CAGR 10-Years
18%
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Net Income (Common)
₩184.4B
|
CAGR 3-Years
100%
|
CAGR 5-Years
40%
|
CAGR 10-Years
15%
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Net Income (Common)
-₩5.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Net Income (Common)
₩11.5B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
10%
|
See Also
What is SK Biopharmaceuticals Co Ltd's Net Income (Common)?
Net Income (Common)
-32.9B
KRW
Based on the financial report for Dec 31, 2023, SK Biopharmaceuticals Co Ltd's Net Income (Common) amounts to -32.9B KRW.
What is SK Biopharmaceuticals Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
25%
Over the last year, the Net Income (Common) growth was 76%. The average annual Net Income (Common) growth rates for SK Biopharmaceuticals Co Ltd have been 49% over the past three years , 25% over the past five years .
You don't have any saved screeners yet
